UTI Healthcare Fund Direct Growth
NAV as on 21-04-2025
₹ 303.03
▲0.6%
1D
Inception Returns
16.2%
/yr
Historical NAV & Returns
Absolute
▲
▼
376 people have invested ₹ 52.5L in UTI Healthcare Fund Direct Growth in the last three months
About UTI Healthcare Fund Direct Growth
UTI Healthcare Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by . The fund could potentially beat inflation in the long-run.
Key Parameters
- UTI Healthcare Fund Direct Growth has ₹1042 Cr worth of assets under management (AUM) as on Mar 2025 and is less than category average.
- The fund has an expense ratio 1.2.
Returns
UTI Healthcare Fund Direct Growth has given a CAGR return of 16.22% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 23.99%, 20.34% and 23.36% respectively.
Holdings
UTI Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Ajanta Pharma Ltd, Dr Reddy's Laboratories Ltd, Glenmark Pharmaceuticals Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of UTI Healthcare Fund Direct Growth
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. UTI Healthcare Fund Direct Growth has no lock in period.
UTI Healthcare Fund Direct Growth Overview
| Expense ratio | 1.2% |
Benchmark | BSE Healthcare TR INR |
| AUM | ₹1042 Cr |
| Inception Date | 1 January, 2013 |
| Min Lumpsum/SIP | ₹5000/₹500 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 24.75% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
INDmoney Rank for UTI Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
Beats FD returns for both 3Y & 5Y duration
5Y returns in the bottom 25% of the category
Trailing Returns
as on (21-Apr-25)
Fund Distribution
as on (31-Mar-25)
Small cap
41.5%
Large cap
28.9%
Mid cap
27.8%
Sector Allocation
Health
98.8%
Basic Materials
1.2%
All changes are between Jan'25 and Mar'25
- This fund’s returns stands at 8.18% whereas the fund’s underlying benchmark Nifty 500 returns stands at 7.25% as on Mar'25
- This fund outperformed Nifty 500 by 0.93% in Mar'25
- AUM of the fund stands at 1K Cr as of Mar'25
- AUM decreased by 15.1 Cr between Mar'25 and Feb'25
Top Stocks bought last month
Sun Pharmaceuticals Industries Ltd's allocation increased from 10.93% to 11.65%
Aster DM Healthcare Ltd Ordinary Shares's allocation increased from 1.87% to 2.27%
Apollo Hospitals Enterprise Ltd's allocation increased from 3.22% to 3.57%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 6.19 % to 5.81 %
Ajanta Pharma Ltd's allocation decreased from 4.43 % to 4.4 %
Dr Reddy's Laboratories Ltd's allocation decreased from 4.89 % to 4.35 %
Mid Cap allocation has gone up from 26.3% to 27.8%
Large Cap allocation has gone up from 28.9% to 28.9%
Small Cap allocation has gone down from 43.5% to 41.5%
Cash allocation has gone up from 0.4% to 0.8%
Top 2 Sectors in March were Health, Basic Materials
Mar'25
Health
99%
Basic Materials
1%
Feb'25
Health
99%
Basic Materials
1%
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 11.65% | -3.4% | |
 Cipla Ltd | 5.81% | -9.7% | |
 Ajanta Pharma Ltd | 4.4% | -7.2% | |
 Dr Reddy's Laboratories Ltd | 4.35% | -8.5% | |
 Glenmark Pharmaceuticals Ltd | 4.07% | -11% |
See all
Funds | 1Y Returns | 3Y Returns | 5Y Returns | Since Inception |
|---|---|---|---|---|
UTI Healthcare Fund Direct Growth | 23.99% | 20.34% | 23.36% | 16.22% |
 SBI Healthcare Opportunities Fund Direct Growth | 24.35% | 23.6% | 26.52% | 18.28% |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth | 23.74% | 23.85% | 26.59% | 22.57% |
 LIC MF Healthcare Fund Direct Growth | 21.83% | 16.88% | 19.41% | 20.14% |
See all
Top Growth Drivers | 1M Return |
|---|---|
 Krishna Institute of Medical Sciences Ltd | 6.6% |
Loading...
We are taking more time than usual
Fund House
UTI Asset Management Co Ltd
Total Schemes
Total AUM
₹2.21L Cr
as on 31-Mar-2025
Address
PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051
Phone
+912266786666
Website
pms_care@uti.co.in
Mutual Fund Insights
Over the last 1 year, this fund has decreased expense ratio by 11.1% moving from 1.35 to 1.20.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 31.8% return, outperforming this fund by 7.81%.
In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 26.59% return, outperforming this fund by 3.23% per annum.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.2% which is lower than the category average expense ratio of 1.4%.
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 23.93% return, outperforming this fund by 3.59% per annum.
Over the last 3 months, this fund has experienced a 15.7% drop in AUM moving from 1.23K Cr to 1.04K Cr.
UTI Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 16.22% since inception which is less than its category average return of 17.31%
Fund Allocations
This fund has an allocation of 99.21% in Equity, 0% in Debt and 0.79% in Cash related instruments
AUM size ₹1042 Cr
This fund has AUM of ₹1042 Cr which is less than its category average of ₹ 1821 Cr
Expense Ratio 1.2%
This fund has an expense ratio of 1.2% which is less than its category average expense ratio of 1.44%
Most Popular Comparisons
- Compare
UTI Healthcare FundVs
Nippon India Pharma Fund Direct Growth
- Compare
- UTI Healthcare FundVs
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
- Compare
- UTI Healthcare FundVs
SBI Healthcare Opportunities Fund Direct Growth
- Compare
- UTI Healthcare FundVs
DSP Healthcare Fund Direct Growth
- Compare
- UTI Healthcare FundVs
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
More funds from UTI
5Y CAGR
▲ 30.62
5Y CAGR
▲ 28.22
5Y CAGR
▲ 26.81
Frequently Asked Questions for UTI Healthcare Fund Direct Growth
The current NAV of UTI Healthcare Fund Direct Growth is ₹303.03 as on 21-Apr-2025.
Existing (Absolute + CAGR) as on 21-Apr-2025.
UTI Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -0.51% | -0.51% |
6 Month Returns | -5.09% | -5.09% |
1 Year Returns | 23.99% | 23.99% |
3 Years Returns | 74.28% | 20.34% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.2% as on March 2025
₹1042 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(11.65%), Cipla Ltd(5.81%), Ajanta Pharma Ltd(4.4%), Dr Reddy's Laboratories Ltd(4.35%), Glenmark Pharmaceuticals Ltd(4.07%) as on March 2025
The alpha ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
UTI Healthcare Fund Direct Growth | 2.03 | 0.99 | 0.95 |
As on March 2025
The alpha for UTI Healthcare Fund Direct Growth is calculated against BSE Healthcare TR INR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
UTI Healthcare Fund Direct Growth | 1.01 | 0.95 | 0.95 |
As on March 2025
The Beta for UTI Healthcare Fund Direct Growth is calculated with BSE Healthcare TR INR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
UTI Healthcare Fund Direct Growth | 0.71 | 0.84 | 1.13 |
As on March 2025
The sharpe ratio for UTI Healthcare Fund Direct Growth is calculated with BSE Healthcare TR INR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the UTI Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
UTI Healthcare Fund Direct Growth | 20.55 | 16.7 | 19.39 |
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.49 as on March 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.18 as on March 2025. It tells the consistency of the fund in generating superior risk-adjusted performance
The Exit load of UTI Healthcare Fund Direct Growth is 1%